🔎 Trials Near Me

Gara Jalqabaatti › Luukemiya Mayiloodii Faasii Keessummaa › New York

Qorannoo klinikaalii Luukemiya Mayiloodii Faasii Keessummaa New York keessatti

Qorannoo 5 Luukemiya Mayiloodii Faasii Keessummaa f New York keessatti hirmaatuu jiru.

Magaalota New York keessatti

Takkalaa qorannoo (Ingiliffa)

Study of Olverembatinib (HQP1351) in Patients With CML-CP

  • Ascentage Investigative Site #1068, Rochester
  • Ascentage Investigative Site #1053, Shirley
  • Ascentage Investigative Site #1160, Stony Brook
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT06423911

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04838041

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

  • NY Cancer and Blood Specialists, East Setauket
  • SUNY Upstate Medical University, Syracuse
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 20-Ado-2026 · NCT07091019

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, The Bronx
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT05304377

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)

  • Memorial Sloan Kettering Cancer Center - Main Campus, New York
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 12-Ama-2026 · NCT06163430

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.